Volume 2 Issue 1

Volume 2 Issue 1

______________________________________________________________________________________________________________________________

Research Article

Role of Vascular Endothelial Growth Factor Receptor Inhibitors in Refractory Cervical Cancer

Ghazaleh Shoja E Razavi*, Giridhar M.N.V*, Timothy Allen

This review article focuses on the past and future aspects of vascular endothelial growth factor inhibitors in Cervical Cancer. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is considered to play a vital function in the tumor development and metastasis. Therefore, VEGF-inhibitors are being actively considered as prospective anticancer treatment. The most widely studied tyrosine kinase inhibitors that target VEGF or anti- VEGF monoclonal antibodies and receptors, promise significant results in clinical trials.

Full textDownload PDF

______________________________________________________________________________________________________________________________

Review Article

Proteasome Inhibition in Lymphoproliferative Disorder

Timothy Allen, MD, Ph.D, Giridhar M.N.V, MD,MBA*, Ghazaleh Shoja E Razavi MD*

Proteasomes are multi-subunit protein complexes, which present numerous targets for therapeutic interference. The most commonly used proteasome is 26S proteasome, which contains one 20S proteolytic core subunit and two 19S regulatory cap subunits. There are three different types of active sites of 20S proteolytic core and both, natural and synthetic proteasome inhibitors have been developed for this active site. The bortezomib is a Peptide boronate proteasome inhibitor and it targets the vital degradation process of intracellular protein, through proteasome.

Full textDownload PDF